It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gonadal sexual fate in mammals is determined during embryonic development and must be actively maintained in adulthood. In the mouse ovary, oestrogen receptors and FOXL2 protect ovarian granulosa cells from transdifferentiation into Sertoli cells, their testicular counterpart. However, the mechanism underlying their protective effect is unknown. Here, we show that TRIM28 is required to prevent female-to-male sex reversal of the mouse ovary after birth. We found that upon loss of Trim28, ovarian granulosa cells transdifferentiate to Sertoli cells through an intermediate cell type, different from gonadal embryonic progenitors. TRIM28 is recruited on chromatin in the proximity of FOXL2 to maintain the ovarian pathway and to repress testicular-specific genes. The role of TRIM28 in ovarian maintenance depends on its E3-SUMO ligase activity that regulates the sex-specific SUMOylation profile of ovarian-specific genes. Our study identifies TRIM28 as a key factor in protecting the adult ovary from the testicular pathway.
Gonadal fate in mammals is determined during embryogenesis and is actively maintained in adulthood. This study shows that E3-SUMO ligase activity of TRIM28 is required for ovarian identity maintenance and testicular-specific gene repression in mouse adult ovary; in its absence, ovarian granulosa cells transdifferentiate to Sertoli cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 CNRS UMR9002 University of Montpellier, Institute of Human Genetics, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141); Univ. Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France (GRID:grid.488493.a) (ISNI:0000 0004 0383 684X)
2 CNRS UMR9002 University of Montpellier, Institute of Human Genetics, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
3 University of Geneva CMU, lab E09.2750.B 1, Department of Genetic Medicine and Development, Faculty of Medicine, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988)
4 GenomEast platform, IGBMC, 1, rue Laurent Fries, Illkirch-Graffenstaden, France (GRID:grid.420255.4) (ISNI:0000 0004 0638 2716)
5 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
6 Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Gif-sur-Yvette, France (GRID:grid.457334.2) (ISNI:0000 0001 0667 2738)
7 University of Montpellier, CNRS, Institut de Génétique Moléculaire de Montpellier (IGMM), Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
8 Institut de Recherche en Cancérologie de Montpellier, IRCM, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France (GRID:grid.488845.d) (ISNI:0000 0004 0624 6108)
9 University of Melbourne, Department of Anatomy and Physiology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)